Clinical trials: Nerve Degeneration
Insomnia
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia.
- Trial name
- Neuro-DORA (NCT06823752)
- Testing
- Lemborexant 10 MG
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Woolcock Institute of Medical Research
Mitochondrial Myopathies, Mitochondrial DNA Mutation
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
This study is an observational longitudinal study involving the use of MRIs and video recordings taken at home of patients completing basic tasks.
- Conditions
- Mitochondrial Myopathies, Mitochondrial DNA Mutation, Mitochondrial Diseases, Chronic Progressive External Ophthalmoplegia With Myopathy
- Trial name
- NCT05012358
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Eye Diseases Hereditary, Retinal Disease
Inherited Retinal Degenerative Disease Registry
The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation.
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome
- Trial name
- MRTR (NCT02435940)
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Foundation Fighting Blindness
Mild Cognitive Impairment, Obstructive Sleep Apnea
Evaluation of Trazodone in OSA-MCI
Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disease. Before progressing to AD, individuals may experience mild cognitive impairment (MCI).
- Trial name
- NCT05209035
- Testing
- Trazodone
- Where
- Hong Kong
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Parkinson Disease, Movement Disorders
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
Veterans with mid to later stage Parkinson's disease (PD) may not be able to work out as hard as they need to, to prevent brain cell loss.
- Conditions
- Parkinson Disease, Movement Disorders, Neurodegeneration
- Trial name
- HI-LITE (NCT06088355)
- Testing
- HV-PDAE: High Volume Partnered Dance Aerobic Exercise, MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise, MV-WALK: Moderate Volume Walking
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease, Exercise Therapy
Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease
Parkinson's disease (PD) is a difficult to treat condition that impairs mobility and thinking. It is not fully treated by drugs and surgery. Two priority issues for most people with PD are "OFF-time" and Cognitive impairment.
- Conditions
- Parkinson's Disease, Exercise Therapy, Cognition
- Trial name
- PDAE in PD (NCT04122690)
- Testing
- PDAE, WAE
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- VA Office of Research and Development
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Multiple Sclerosis
Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
In this study the investigators will use PET and 11C-Flumazenil to visualize and quantify neuronal injury in the cortex and the deep gray matter of Multiple Sclerosis patients at an early stage.
- Trial name
- Flumatep_2 (NCT01651520)
- Testing
- PET with 11C-Flumazenil
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Macular Degeneration, Regional Blood Flow
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Age related macula degeneration is one of the most common sight threatening diseases of the elderly. The so called wet form of AMD is caused by choroidal neovascularisation (CNV) of pathological vessels, which lead to leakage…
- Conditions
- Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
- Trial name
- NCT00709657
- Testing
- ranibizumab, bevacizumab or pegaptanib
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
COVID-19 Infection, Encephalitis
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache).
- Trial name
- MARNEVO-Covid (NCT04361344)
- Testing
- blood samples
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Centre Hospitalier de PAU
Parkinson Disease, Parkinsonism
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive…
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive
- Trial name
- MTMD (NCT03076671)
- Testing
- Palliative Care
- Where
- 2 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.
- Trial name
- BrainAgeMS (NCT06221631)
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Back Pain, Radiculopathy Lumbar
Threshold Response of Lumbar Selective Nerve Root Block in Predicting Good Outcome Following Lumbar Foraminotomy
SNRB, as measured by the change in pain and objective functional ability, can solicit crucial information regarding a patient's clinical picture and can predict a patient's outcome post-surgery.
- Conditions
- Back Pain, Radiculopathy Lumbar, Degenerative Lumbar Spinal Stenosis
- Trial name
- NCT03801356
- Testing
- Selective Nerve Root Block
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Cleveland Clinic
Diabetic Retinopathy, Diabetic Retinopathy Associated with Type 2 Diabetes Mellitus
Early Retinal Neurodegeneration As Risk Factor, Biomarker and Pharmacological Target of Diabetic Retinopathy
Despite the evidence that diabetic retinopathy (DR) remains the first cause of blindness among the working-age population, it lacks a specific preventive treatment.
- Trial name
- 2022-12376008 (NCT06582472)
- Testing
- Ophthalmological examination including imaging assessments, confocal analysis of cornea, Dynamic Vessel Analyzer (DVA)
- Where
- 2 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Diabetic Retinopathy, Neurodegeneration
Glycemic Control and Retinal Microvascular Changes
The goal of this prospective, observational study is to compare in the association of glycemic control and retinal microvascular changes in patients with type 2 diabetes mellitus (T2DM) without diabetic retinopathy (DR).
- Conditions
- Diabetic Retinopathy, Neurodegeneration, Blood Sugar; High
- Trial name
- NCT06150495
- Where
- South Korea
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Multiple Sclerosis
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients.
- Trial name
- NCT02651545
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Parkinson Disease, Physical Activity
Neuroplasticity in Parkinson´s Disease After Training
This project aims to determine the effects of the HiBalance program on neuroplastic changes in people with mild to moderate Parkinson´s disease.
- Conditions
- Parkinson Disease, Physical Activity, Gait Disorders, Neurologic, Neural Degeneration
- Trial name
- BETA-PD (NCT03213873)
- Testing
- HiBalance, Speech and communication therapy
- Where
- Sweden
- Volunteers
- 95 people
- Sponsor
- Karolinska Institutet
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC